Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Inflectra / Remsima (infliximab biosimilar) by Year
Inflectra / Remsima (infliximab biosimilar) — International reported YoY (%) (%)
Pfizer Inflectra / Remsima (infliximab biosimilar): -44.0% in FY2025, down 47.0 pts from a year earlier. That is the lowest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Inflectra | 646 | 509 | 27% | 27% | 511 | 268 | 91% | 134 | 241 | (44%) | (43%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Inflectra / Remsima (infliximab biosimilar) (%), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inflectra-yoy-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.